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Abstract
Background: Whereas the complement system alterations contribute to schizophrenia, complement receptors and
regulators are little studied. We investigated complement receptor type 1 (CR1) expression on blood cells, the
levels of circulating immune complexes (CIC) containing ligands of CR1, C1q complement protein and fragments
of C3 complement protein (C1q-CIC, C3d-CIC), and CR1 C5507G functional polymorphism in schizophrenia patients
and controls.
Results: We found an increased C1q-CIC level and CR1 expression on blood cells, elevated number of CR1 positive
erythrocytes and reduced number of CR1 positive lymphocytes and monocytes in patients compared to controls.
No difference in the levels of C3d-CIC between groups was observed. Higher CR1 expression on erythrocytes in CC
genotype versus CG+GG for both groups was detected, whereas no difference was observed for other cell
populations. Our results indicated that schizophrenia is associated with the increased CR1 expression and C1q-CIC
level.
Conclusions: Our study for the first time indicated that schizophrenia is associated with the increased CR1
expression and C1q-CIC level. Further studies in other ethnic groups are needed to replicate these findings.
Background
Complement receptor type 1 (CR1; CD35; C3b/C4b
receptor) is a multifunctional receptor, which is
expressed in the majority of peripheral blood cells [1-4],
with high affinity to complement components C1q, C3,
C4 [5-8] and mannose-binding lectin [9]. Binding of CR1
to opsonic fragments of the complement C3 and C4
components (C3b, C4b, iC3b, and C3dg) and to the com-
plement component C1q attached to immune complexes
(IC), foreign or damaged host cells serves to mediate
clearance of IC (on erythrocytes (E)) [4,10] and phagocy-
tosis of complement-coated particles (on leukocytes)
[3,11,12]. In addition, interaction of CR1 with its ligands
plays further roles in regulation of lymphocyte (L) activity
by promoting secretion of interleukin (IL)-1a,I L - 1 b, and
prostaglandins [13]. Furthermore, CR1 plays a role in
antigen presentation to B cells [12]. In addition to mem-
brane-bound CR1, leukocytes also release soluble form of
CR1, which is a potent inhibitor of both the classical and
the alternative pathways of complement activation by
exhibiting decay-accelerating activity for both C3 and C5
convertases, as well as cofactor activity for factor I-
mediated cleavage of C3b and C4b [10,13,14].
A number of studies suggest the involvement of
alterations in the immune response, including autoim-
mune and inflammatory mechanisms, in the aetiopatho-
genesis of schizophrenia [15-17]. Alterations in
functional activities of classical, alternative and lectin
pathways of complement, a major mediator of the
immune response, as well as changes in blood levels and
expression profiles of its C1q, C3, and C4 components
have been detected in schizophrenia-affected subjects
[18-22]. However, little is known about receptors and
regulators of the complement system in schizophrenia.
Here CR1 represents a special interest, accounting for a
positive genome-wide linkage of schizophrenia with the
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C5507G single nucleotide polymorphism (SNP) in exon
33 has been shown to be associated with some diseases
characterized by altered inflammatory response [24,25],
and changes in CR1 expression have been shown in
patients with a variety of inflammatory and autoimmune
diseases [14,26-28].
In the present study we investigated the expression of
CR1 on E and leukocytes in patients with schizophrenia
and evaluated the possible association of CR1 C5507G
functional polymorphism with this disorder. In addition,
in the blood of schizophrenia affected subjects the levels
of circulating immune complexes (CIC) containing nat-
ural ligands of CR1, namely C1q and fragments of C3,
were also determined. A control group included healthy
subjects without family history of schizophrenia.
Results
CR1 expression on blood cells
The expression of CR1 on blood cells was quantified by
flow cytometry. The results obtained are shown on Fig-
ure 1 and in table 1. According to the data obtained,
CR1 expression levels for erythrocytes were significantly
higher in patients compared to controls and were posi-
tively correlated with the duration of schizophrenia (rho
= 0.637, p = 0.004). The same applies to the percentage
of CR1-positive E (patients: 83.84 [2.66] % versus con-
trols: 75.94 [6.74] %, p = 7.48E-07). Interestingly, the
CR1 expression on subpopulation of leukocytes (L,
monocytes (M), and neutrophils (N)) in patients was
significantly higher than in controls (table 1), whereas
the percentage of CR1 positive L (patients: 11.69 [4.03]
% versus controls: 17.26 [6.60] %, p = 4.02E-05) and M
(patients: 1.49 [0.91] % versus controls: 5.19 [1.83] %, p
= 1.42E-10) was significantly lower. No significant differ-
ence was observed in the number of positive N among
studied groups (patients: 64.18 [12.15] % versus controls:
59.93 [9.60] %, p = 0.52). Also, there was no difference
in CR1 expression between smokers and non-smokers
in both groups.
The influence of CR1 C5507G polymorphism on CR1
expression on blood cells
Distribution of genotypes for CR1 C5507G SNP corre-
sponded to the Hardy-Weinberg equilibrium. We found
no significant differences in distribution of genotypes,
allele and carriage frequencies, between the groups of
schizophrenia patients and control subjects (p >0 . 0 5 ,
table 2). The intergroup comparisons showed that in the
CC genotype the levels of CR1 expression on E, M, and
Figure 1 Representative histograms of CR1 measurement on
blood cells. (A) CR1 measurement on erythrocytes: 1 - gated
erythrocyte population. 2 - three fluorescent peaks representing
non-specific (an isotype control) and specific fluorescence
(schizophrenic patients and control subjects). (B) CR1 measurement
on leukocytes: 1 - gated leukocyte populations. 2, 3, 4 - CR1
expression on neutrophils, monocytes, and lymphocytes,
respectively.
Table 1 CR1 expression on blood cells in schizophrenic
patients and controls.
Type of blood cells CR1 expression, RFI p
Patients Controls
Erythrocytes 6.85 [0.89] 6.21 [0.67] 0.001
Lymphocytes 22.35 [8.35] 19.30 [7.90] 0.011
Monocytes 85.55 [46.35] 47.30 [10.00] 1.20E-08
Neutrophils 185.5 [80.00] 140.00 [44.5] 0.003
Table 2 Distribution of CR1 C5507G genotypes and
carriage rates for minor alleles in schizophrenic patients
and controls.
Frequency,
absolute (relative)
OR, CI, p
Patients Controls
CC 75 (0.64) 84(0.59)
Genotype CG 38 (0.32) 55 (0.39)
GG 4 (0.03) 3 (0.02) p = 0.45
Allele C 188 (0.80) 223 (0.79)
G 46 (0.20) 61 (0.21) OR = 1.15, CI: 0.85-1.36, p = 0.53
Carriage C 113 (0.98) 139 (0.97)
G 42 (0.41) 58 (0.36) OR = 0.78, CI: 0.66-1.16, p = 0.63
The data are presented as absolute numbers with proportions in parenthesis.
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whereas in lymphocytes practically equal levels of CR1
expression in both groups were detected (p >0 . 0 5 ) .
Further, we compared the levels of CR1 expression on
the blood cells of normal allele homozygotes and
mutant allele carriers (CG+GG) in patients and controls.
Both groups showed increased CR1 expression on E in
CC homozygous subjects compared to mutant allele car-
riers (Figure 2), whereas levels of CR1 expression on L,
M, and N did not differ between these genotypes (p >
0.05; table 3). No correlation between the CR1 5507G
carriers and clinical characteristics of patients with schi-
zophrenia as well as smokers and non-smokers in both
study groups has been observed. In patients, the frac-
tions of CR1 positive L (CC: 10.45 [5.41] %, CG+GG:
13.51 [4.90] %, p = 0.047) and N (CC: 62.95 [10.90] %,
CG+GG: 70.75 [14.98] %, p = 0.026) were higher in
mutant allele carriers, whereas in control subjects the
number of CR1 positive E were significantly higher in
CC homozygotes (CC: 80.10 [4.54] %, CG+GG: 75.09
[6.48] %, p = 0.023).
Levels of C1q-CIC and C3d-CIC in the blood
The median level of C1q-CIC in the blood serum was
significantly higher in patients compared to controls
(patients 27.25 [4.17] ug/mL versus controls: 24.23
[3.88] ug/mL, p = 0.017), whereas the levels of C3d-CIC
were practically the same in both groups (patients: 14.20
[2.68] ug/mL versus controls14.09 [3.77] ug/mL, p =
0.66). No difference in C3d-CIC and C1q-CIC levels
was observed between CR1 5507 CC homozygotes and
mutant allele carriers in patients (p > 0.05). In contrast,
the G allele carriers in control subjects had significantly
elevated C1q-CIC levels (CG+GG: 25.18 [3.16] ug/mL
versus CC: 22.27 [3.73] ug/mL, p = 0.015). Correlation
analysis showed that CR1 expression levels on blood
cells in control subjects positively correlated with C3d-
CIC levels (rho = 0.44, p = 0.049) and negatively corre-
lated with C1q-CIC levels (rho = -0.42, p =0 . 0 5 8 ) .I n
patients with schizophrenia, no significant correlation
between these parameters was observed. Also, CIC levels
did not differ between smokers and non-smokers among
the patients and controls.
Discussion
Recent studies provide evidence of the involvement of
the complement system alterations in schizophrenia-
associated immune system abnormalities including auto-
immunity and inflammation [13-17]. In this work, we
have extended the current knowledge on the state of the
complement system in schizophrenia by studying CR1
expression on blood cells, the levels of CIC bound to
CR1 ligands, the products of the complement activation,
and the CR1 C5507G functional polymorphism in dis-
eased and healthy subjects.
The results obtained for the first time demonstrate an
increased expression of CR1 on erythrocytes and subpo-
pulations of leukocytes (L, M, and N), accompanied by
the elevated number of CR1 positive E and reduced
number of CR1 positive L and M in patients with schi-
zophrenia as compared to healthy subjects. Regarding
CIC bound to complement-derived CR1 ligands, the
increased levels of C1q-CIC in schizophrenia patients
compared to healthy controls were detected, whereas no
significant difference in the levels of C3d-CIC between
patients and controls was observed.
Changes in CR1 expression on blood cells have been
implicated in a variety of diseases (systemic lupus
erythematosus, acute immunodeficiency syndrome,
rheumatoid arthritis, malarial anaemia, insulin-depen-
dent diabetes, myocardial infarction, etc) associated with
immune system dysfunction, development of inflamma-
tory and autoimmune reactions [26,27,29-33]. Depend-
ing on the diseased condition, these changes may be
determined by either genetic or environmental factors.
The present finding of the increased CR1 expression
levels on blood cells of schizophrenia patients may be a
consequence of the elevated levels of the total popula-
tion of IC in circulation reported by us previously [34],
as well as increased levels of C1q-CIC reported in the
present work. As noted in the introduction, binding of
erythrocyte CR1 to the complement component C1q
attached to IC serves to mediate clearance of IC [5]. In
addition, increase of CR1 expression on leukocytes can
be induced by tumor necrosis factor-a and interleukin-1
[35,36], which are elevated in the blood of schizophrenic
patients [37].
We also observed an enhanced number of CR1 posi-
tive E in schizophrenia patients, while fractions of CR1
Figure 2 The intragroup comparison (n = 117 patients, n = 142
controls) of CR1 expression (RFI) with regard to the CR1 5507
standard allele homozygotes (CC) versus G mutant allele
carriers (CG+GG). The data are expressed as whisker box plots; the
box represents the 25-75th percentiles, the median is indicated by a
bar across the box, the whiskers on each box represent the
minimum and maximum level. P = 0.0003 when comparing levels
between patients and controls.
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to control subjects. Increased number of CR1 positive E
in circulation might be related to the enhanced hemato-
poiesis in response to cytokines and other inflammatory
agents [38], while reduced number of CR1 positive leu-
kocyte subpopulations might be explained by increased
rate of apoptosis induced by antipsychotic treatment
[39-41].
Distributions of the allele and genotype frequencies of
the CR1 C5507G SNP in schizophrenia patients do not
differ from healthy subjects. Therefore, despite the
important role of the complement system in the patho-
genesis of schizophrenia [15-22], its type 1 receptor
gene C5507G polymorphism does not contribute to the
genetic susceptibility to this disease. Further, we com-
pared the levels of CR1 expression on the blood cells of
normal allele homozygotes and mutant allele carriers
(CG+GG) in patients and controls. Both groups showed
increased CR1 expression on E in CC homozygous sub-
jects compared to mutant allele carriers (Figure 2),
whereas levels of CR1 expression on L, M, and L did
not differ between these genotypes (p > 0.05, table 3).
Interestingly, Wilson et al. found the association of
genomic polymorphism with a cis-acting regulatory ele-
ment for the expression of CR1 on E [42].
Conclusions
In conclusion, on the basis of our results we suggested
that schizophrenia is associated with the increased
expression of CR1 on E, L, M, and N accompanied by
the elevated number of CR1 positive E, reduced number
of CR1 positive L and M, and increased level of C1q-
CIC. Interestingly, the levels of CR1 expression on E
were higher in CR1 5507 CC homozygotes when com-
pared to those in G allele carriers both among the
patients with schizophrenia and control subjects.
Further studies in other ethnic groups and populations
are needed to confirm our findings.
Limitations of our study
Some limitations in this study should be noted. Firstly,
we analyzed a relatively small sample size (117 schizo-
phrenia patients and 142 healthy subjects). Secondly, all
the patients with schizophrenia involved in the present
study were receiving antipsychotic treatment.
Methods
Study population
In total, 117 patients with paranoid schizophrenia (F20.0)
and 142 healthy subjects were enrolled in the study. All
subjects were unrelated Armenians living in Armenia. All
patients were diagnosed according to the ICD-10 criteria
[43] by two independent experienced psychiatrists. The
affected subjects (females/males: 60/57, mean age ± SD:
45 ± 10 years, age at the first-onset of illness: mean ± SD:
23 ± 9 years, duration of illness mean ± SD: 19 ± 7 years,
smokers/non-smokers: 33/84) were recruited from the
clinics of the Psychiatric Medical Center of the Ministry
of Health of the Republic of Armenia (MH RA). All
patients were receiving typical antipsychotic haloperidol
and phenazepamum during their treatment. Healthy
volunteers (females/males: 70/72, mean age ± SD: 42 ±
12 years, smokers/non-smokers: 50/72) were recruited
from the Erebouni Medical Center MH RA and served as
a reference control population. They passed a special
examination by two independent experienced psychia-
trists proved no personal or family history of mental dis-
orders. All subjects gave their informed consents to
provide 10 ml of venous blood for the purposes of this
study. The study was approved by the Ethical Committee
of the Institute of Molecular Biology of the National
Academy of Sciences (NAS) RA.
Collection of blood samples
Ten mL of morning fasting venous blood was collected
from each patient and healthy subject using EDTA as
anticoagulant.
Genomic DNA extraction from the whole blood
Genomic DNA samples were isolated from fresh blood
by the standard phenol-chloroform procedure [44] and
stored at -30°C until further use.
Genotyping analysis of CR1 C5507G polymorphism
All DNA samples were genotyped for CR1 C5507G
polymorphism using polymerase chain reaction with
Table 3 Comparison of CR1 expression on blood cells of schizophrenic patients and healthy controls depending on
the CR1 C5507G genotypes.
CR1 expression in patients CR1 expression in controls
Type of blood cells CC CG+GG p CC CG+GG p
Erythrocytes 7.07 [0.31] 6.15 [0.52] 6.57E-08 6.46 [0.46] 5.87 [0.52] 6.88E-06
Lymphocytes 21.70 [8.48] 24.15 [9.33] > 0.05 19.5 [8.25] 18.50 [8.50] > 0.05
Monocytes 80.80 [49.35] 89.60 [45.88] > 0.05 48.86 [9.00] 45.45 [16.75] > 0.05
Neutrophils 190.00 [91.30] 174.50 [65.00] > 0.05 128.00 [42.50] 149.5 [97.00] > 0.05
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tions described elsewhere [45]. The primer sequences
were:
allele C, forward: 5’ATCCGCTGCACAAGTGACCC;
allele G, forward: 5’ATCCGCTGCACAAGTGACCG;
constant reverse: 5’CCCTACTAAATCTGGACCTC
ATC.
The presence/absence of allele-specific amplicons was
visualized by electrophoresis on 2% agarose gel and ethi-
dium bromide fluorescence in reference to a molecular
weight marker.
Isolation of erythrocytes and blood plasma from the
whole blood
Blood samples were centrifuged (700 g × 10 min) at
room temperature. After centrifugation plasma was
separated and a buffy coat was removed. A pellet of E
was washed 3 times by resuspension in BD Cell-
WASH™ solution (BD Biosciences, CA, USA) followed
by centrifugation (700 g × 10 min) at 4°C. After washing
the E resuspended in the same solution were counted
and adjusted to a final concentration of 10
6 cells/mL.
Isolation of leukocytes from the whole blood
Blood samples were treated with BD lysis solution (BD
Biosciences, CA, USA) to lyse E, and then centrifuged
(700 g × 10 min) at room temperature. A pellet, con-
taining leukocytes, was washed 3 times by resuspension
in BD CellWASH™ solution followed by centrifugation
(700 g × 10 min) at room temperature. After washing
the leukocytes were resuspended in the same solution,
counted and adjusted to a final concentration of 10
6
cells/mL.
Measurement of CR1 expression on blood cells
Suspensions of E and L (100 uL of each) were incubated
with FITC-labeled anti-CD35 monoclonal antibody (cat-
alog number 555452, BD Pharmingen, USA) for 1.5-2
hours and then fluorescence at 518 nm (excitation 488
nm) was measured on BD FACScan flow cytometer sup-
plied with BD CellQuest™ Pro 5.2 software (BD
Bioscience, USA). Histogram overlays and dot plots
were produced by WinMDI 2.9 software package. Repre-
sentative pictures of gated cell populations and histo-
g r a m sa r es h o w no nF i g u r e1 .Am a t c h i n gi s o t y p e
control (mouse IgG1 isotype control FITC, catalog num-
ber 11-4714-42, eBioscience, USA) was used to measure
non-specific binding of antibodies to studied cells, and
this value indicated in each histogram with a filled curve
was subtracted from the raw data. E and subpopulations
of leukocytes (L, M, and N) were identified by forward
versus side scatter parameters, and surface expression of
CR1 in each cell population was quantified. An isotype
control was used to estimate the fraction of CR1
positive cells (see Figure 1) which was expressed as a
percentage of positive cells among the cells of particular
population. Surface expression is given in relative fluor-
escence intensity units (RFI) as median [interquartile
range]. Events with RFI exceeding those of isotype con-
trol were considered as CR1-positive, and were gated on
the histogram as a separate subpopulation. The median
RFI was measured to determine CR1 expression in the
marked subpopulation. Histogram overlays and dot
plots were produced by WinMDI 2.9 software package.
Measurement of C1q- and C3d-bound CIC
The levels of C3d- and C1q-bound CIC (C3d-CIC and
C1q-CIC, respectively) were measured in plasma by
enzyme-linked immunosorbent assay (ELISA) using
commercially available kits (IMTEC-C3d-CIC and
IMTEC-C1q-CIC, Human GmBH, Germany) according
to manufacturer’s instructions. The level of C3d-CIC
reflects total concentration of CIC with bound C3 frag-
ments (C3b, iC3b, and C3dg), which contain the frag-
ment of the C3 alpha polypeptide chain known as the
“d” fragment.
Statistical analysis
The distributions of genotypes for CR1 C5507G were
checked for correspondence to Hardy-Weinberg (H-W)
equilibrium. In order to find potential relevance of the
selected CR1 SNP to schizophrenia, its allele (gene) and
phenotype frequencies (carriage rates) in patients and
control subjects were compared. The significance of dif-
ferences between allele and phenotype frequencies cal-
culated on the base of the number of observed
genotypes was determined using Pearson’sC h i - s q u a r e
test. The odds ratio (OR), 95% confidence interval (CI),
and Pearson’s p-value were calculated. The Mann-Whit-
ney U test was used for evaluation of intergroup differ-
ences in the levels of CR1 expression, C1q-CIC, and
C3d-CIC and percentage of CR1 positive cells. Survival
analysis was performed to evaluate the possible associa-
tion between clinical/demographic characteristics of
schizophrenia patients and genotypes and expression
levels observed.
Group statistics, otherwise indicated, was presented as
median [interquartile range]. Spearman’s rank correla-
tion coefficient (rho) was calculated to assess relation-
ships between measured parameters. P-values less than
0.05 were considered significant. Statistical analysis was
performed using “Graphpad Prism” (GraphPad Software
Inc., USA) software.
List of abbreviations
CR1: complement receptor type 1; C1q: q subcomponent of complement
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